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Abstract
Mepilex Border Sacrum and Heel dressings are self-adherent, multilayer foam dressings designed for use on the heel and 
sacrum aiming to prevent pressure ulcers. The dressings are used in addition to standard care protocols for pressure ulcer 
prevention. The National Institute for Health and Care Excellence (NICE) selected Mepilex Border Sacrum and Heel dress-
ings for evaluation. The External Assessment Centre (EAC) critiqued the company’s submission. Thirteen studies (four 
randomised controlled trials and nine nonrandomised comparative studies) were included. The majority of studies compared 
Mepilex Border Sacrum dressings (plus standard care) with standard care alone. Comparative evidence for Mepilex Border 
Heel dressings was limited. A meta-analysis indicated a non-statistically significant difference in favour of Mepilex Border 
Sacrum dressings for pressure ulcer incidence [RR 0.51 (95% CI 0.22–1.18)]. The company produced a de novo cost model, 
which was critiqued by the EAC. After the EAC updated input parameters, cost savings of £19 per patient compared with 
standard care alone for pressure ulcer prevention were estimated with Mepilex Border dressings predicted to be cost sav-
ing in 57% of iterations. The Medical Technologies Advisory Committee reviewed the evidence and judged that, although 
Mepilex Border Heel and Sacrum dressings have potential to prevent pressure ulcers in people who are considered to be 
at risk in acute care settings, further evidence is required to address uncertainties around the claimed benefits of the dress-
ings and the incidence of pressure ulcers in an NHS acute-care setting. After a public consultation, NICE published this as 
Medical Technology Guidance 40.
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Key Points for Decision Makers 
Mepilex Border Heel and Sacrum dressings show 
promise for preventing pressure ulcers in people who are 
considered to be at risk in acute-care settings. However, 
there is currently insufficient evidence to support the 
case for routine adoption in the NHS.
Research is recommended to address uncertainties about 
the claimed benefits of using Mepilex Border Heel and 
Sacrum dressings. This research should also explore 
issues such as:
 the incidence of heel and sacrum pressure ulcers in NHS 
acute-care settings
 criteria for patient selection to reduce pressure ulcer 
incidence with Mepilex Border Heel and Sacrum dress-
ings in addition to standard care.
1 Introduction
The National Institute for Health and Care Excellence 
(NICE) evaluates medical technologies and, where appro-
priate, produces evidence-based guidance to encourage 
adoption of novel and innovative medical devices and diag-
nostics within the National Health Service (NHS) in Eng-
land. NICE’s Medical Technologies Evaluation Programme 
(MTEP) receives notifications of medical technologies, most 
commonly from product manufacturers, which are selected 
for evaluation based on criteria, including whether they 
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have the potential to offer clinical benefits to patients and/or 
reduce costs compared with standard care.
A scope is produced by NICE detailing the decision prob-
lem to be addressed, and clinical and economic evidence 
submitted by the company is assessed independently by an 
External Assessment Centre (EAC). Following the EAC’s 
evaluation and public consultation period, the Medical Tech-
nologies Advisory Committee (MTAC) develops guidance. 
The methodology adopted by the MTEP is described in more 
detail in its methods and process guides [1, 2].
In January 2019, NICE issued final guidance on Mepi-
lex Border Sacrum and Heel dressings for use with patients 
at risk or at high risk of pressure ulcers. Mepilex Border 
Sacrum and Heel dressings are self-adherent, five-layer foam 
dressings specifically for use on the heel and sacrum. The 
dressings have been designed to reduce friction between 
the skin and the dressing, prevent stretch or tear of the skin 
and absorb moisture, with the aim of preventing the occur-
rence of pressure ulcers. The EAC critiquing the evidence 
was the Newcastle upon Tyne NHS Foundation Trust and 
York Health Economics Consortium partnership. Clinical 
experts, identified using NICE’s published processes, pro-
vided advice to the EAC and MTAC.
This article includes an overview of the clinical and cost-
effectiveness evidence submitted by the company, the EAC’s 
report and the subsequent development of the NICE guid-
ance. Full documentation of the process, final guidance and 
supporting evidence is available on the NICE website [3].
2  Background to the Indication and Devices
Pressure ulcers are localised injuries to the skin and/or 
underlying tissue as a result of pressure, or pressure in com-
bination with shear [4]. Pressure ulcers can range in severity 
and can be classified into the following categories or stages 
[5]:
• Stage 1 Intact skin with non-blanchable erythema of 
a localised area. Discoloration of the skin, warmth, 
oedema, hardness or pain may also be present.
• Stage 2 Partial thickness loss of dermis presenting as a 
shallow open ulcer with a red/pink wound bed, without 
slough or bruising. It may also present as an intact or 
open/ruptured serum-filled blister.
• Stage 3 Full thickness tissue loss. Subcutaneous fat may 
be visible, but bone, tendon or muscle are not exposed. 
Some slough may be present. It may include undermining 
and tunnelling.
• Stage 4 Full thickness tissue loss with exposed bone, ten-
don or muscle. Slough or eschar may be present. It often 
includes undermining and tunnelling.
Pressure ulcers can have a significant impact on a 
patient’s quality of life, both physically and psychologically. 
They can also lead to further health complications such as 
infection, extended hospital stays, restricted rehabilitation 
and restricted treatment options for other medical condi-
tions [6, 7].
All patients are at risk of pressure ulcers. However, Mepi-
lex Border dressings have been indicated for use in people 
identified as either ‘at risk’ or ‘at high risk’ of developing 
a pressure ulcer.
Guy [8] reports that risk factors for pressure ulcers 
include:
• Reduced mobility or immobility—pain is a warning sig-
nal that pressure has been exerted for too long, which 
normally triggers movement. Patients who are unable to 
move will require the help of someone else in order to do 
so.
• Lack of sensation—if pain signals are absent, patients 
may not be aware that damage is occurring and will not 
realise that they should move. This includes anything 
which may impair sensation including unconsciousness, 
analgesia or alcohol/substance abuse.
• Nutritional status—it is widely accepted that undernour-
ished people are at increased risk of pressure ulcer devel-
opment.
• Compromised vascular supply—skin with compromised 
vascular supply may deteriorate more rapidly. Patients 
with peripheral arterial disease, or patients who experi-
ence events such as cardiac arrest or hypovolaemic shock 
may be at increased risk.
• Moisture—skin that is constantly or often moist is at 
increased risk of pressure ulcer.
• Friction and shear—these forces are additional to pres-
sure, and further hamper blood flow by stretching and 
contorting blood vessels. This is most commonly seen 
in the sacrum and heels.
In addition to the risk factors described above, clinical 
experts also indicated that the following conditions may also 
increase the risk of developing a pressure ulcer: diabetes, 
dementia, significant cognitive impairment, tremors, leg 
spasms, leg oedema, critical illness, low or high body mass 
index (BMI), terminal illness, extremes of age, previous his-
tory of pressure damage and long theatre times.
Risk assessment tools such as the Braden scale, the 
Waterlow score and the Norton risk-assessment scale are 
recommended by NICE to be used alongside clinical judge-
ment to determine whether a person is at increased risk of 
developing a pressure ulcer [9].
In addition to risk assessment for all people admitted to 
secondary care, standard care protocols for prevention of 
pressure ulcers recommended by NICE [9] include:
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• Skin assessment either once daily or more often for those 
assessed as being at high risk of a pressure ulcer, and less 
frequently for those at lower risk.
• Repositioning at least every 6 h for people at risk, or 
every 4 h for people at high risk of developing a pressure 
ulcer.
• Use of specialist equipment such as high-specification 
foam mattresses/cushions and/or devices to offload heel 
pressure.
• Use of barrier creams in people at high risk of developing 
a moisture lesion or incontinence-associated dermatitis, 
as identified by skin assessment.
Mepilex Border dressings are intended for use in addition 
to standard care protocols for pressure ulcer prevention.
3  Decision Problem (Scope)
3.1  Population
The population described in the scope included patients at 
risk or at high risk of pressure ulcers in an acute care setting 
as defined using a validated assessment scale. The company 
also included evidence on patients in an aged-care setting; 
however, this was subsequently excluded by the EAC in line 
with the scope. The majority of evidence identified by both 
the company and the EAC was in high-risk patients.
3.2  Intervention
Interventions identified in the scope were Mepilex Border 
Heel dressings and Mepilex Border Sacrum dressings used 
as an adjunct to standard NHS clinical practice. The com-
pany (Mölnlycke Health Care) included evidence on Mepilex 
Border general dressings (not specific to heel or sacrum) and 
Mepilex dressings (a 3-layer version of the Mepilex Border 
dressing). The EAC included evidence on Mepilex Border 
general dressings (when applied to the heel or sacrum) but 
excluded evidence on the Mepilex three-layer dressings as 
these were deemed to be out of scope given that they are a 
separate device utilising different technology.
3.3  Comparator
The comparator listed in the scope was standard NHS clini-
cal practice for patients considered ‘at risk’ or ‘at high risk’ 
of pressure ulcers, which may involve a combination of:
• Risk assessment with a validated scale.
• Skin assessment.
• Frequent repositioning.
• Pressure redistribution devices such as high-specification 
foam mattresses.
• Other dressings or skin applications.
• Information.
• Barrier cream.
Evidence submitted by the company included studies con-
ducted in countries outside of the UK and, therefore, stand-
ard care varied across studies and was not always consistent 
with the scope. Neither the company nor the EAC identified 
any comparative UK evidence.
3.4  Outcomes
The company’s submission addressed five of the ten out-
comes identified in the scope. Specifically, evidence was 
provided for the incidence of pressure ulcers, stage of pres-
sure ulcers, level of patient satisfaction, level of pain and 
discomfort and impact on quality of life, and ease of use 
of product. No evidence was identified by either the com-
pany or the EAC on the following outcomes specified in the 
scope: incidence of skin breakdown at the heel and sacrum, 
additional length of hospital stay as a result of pressure 
ulcers, patient compliance with pressure ulcer prevention 
strategies, complications avoided from pressure ulcer pre-
vention strategies and device-related adverse events.
4  Review of Clinical and Economic Evidence
Section 4.1 summarises the clinical evidence submitted, 
the EAC’s critique of the clinical evidence and the EAC’s 
additional work. Section 4.2 provides the same detail for the 
economic evidence.
4.1  Clinical Effectiveness Evidence
4.1.1  Company’s Review of Clinical Effectiveness Evidence
The company identified 203 records through its literature 
search and included 34 studies reported across 35 records, 
comprising:
• Five randomised controlled trials (RCTs), including four 
[10–13] published and one unpublished. Since the com-
pany submitted its report, a full publication became avail-
able for the unpublished trial [14].
• Twenty-two observational studies, including 14 pub-
lished [15–28] and 8 unpublished [29–36].
• Seven published systematic reviews [37–40].
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The company completed the relevant results and method-
ology tables for each included study and attempted to criti-
cally appraise the evidence. The company did not synthe-
sise the outcomes using a meta-analysis. Instead, a narrative 
synthesis of study results was provided, and the company 
commented on the synthesis conducted in several published 
systematic reviews.
4.1.2  Critique of Clinical Effectiveness Evidence
The EAC identified several limitations to the company’s 
search methodology, and their selection criteria were not 
in full alignment with the NICE scope. The EAC re-ran the 
company’s literature search as far as possible, conducted 
a de novo search and realigned the selection criteria with 
the scope to identify relevant clinical evidence on Mepilex 
Border Heel, Mepilex Border Sacrum and Mepilex Border 
(when applied to the heel or sacrum) dressings. Full details 
of the EAC’s search strategies are described in the assess-
ment report [41]. The EAC identified 1242 records, which 
were assessed by 2 reviewers (see Fig. 1).
Due to the sufficient volume of comparative evidence 
identified, the EAC limited eligible study designs to RCTs 
and non-randomised comparative studies. Single-arm stud-
ies were considered for adverse events only. Thirteen studies 
reported across 23 records were eligible for inclusion in the 
review. The reviewed evidence comprised:
• Four RCTs. Three of which were identified and included 
by the company [10, 11, 13] and one newly identified by 
the EAC [42].
• Nine comparative observational studies [17–19, 23–25, 
28, 33, 36]. All of these studies were identified and 
included by the company.
All of the studies included by the company were success-
fully identified by the EAC. However, 22 studies (2 RCTs 
[12, 14, 25], 2 non-randomised comparative observational 
studies [21, 22], 12 single-arm studies [15, 16, 20, 26, 27, 
29–32, 34, 35, 43] and 7 systematic reviews [37–40, 44–46]) 
were subsequently excluded based on the EAC’s updated eli-
gibility criteria. Detailed reasons for excluding these studies 
and detailed information on the studies included by the EAC 
are reported in the EAC’s assessment report [41].
The four included RCTs were published as full papers and 
compared Mepilex Border Sacrum plus standard care with 
standard care alone [10, 11, 13, 42]. Standard care varied 
across the RCTs, but specific components that aligned with 
the scope included pressure redistribution [10, 11, 13, 42], 
regular repositioning and skin care [10, 11], skin assess-
ment [42] and risk assessment by Braden score [13]. The 
populations in all four RCTs were well matched with the 
scope of the decision problem, recruiting adult patients at 
high risk of pressure ulcers in acute care settings. All four 
trials were conducted outside of the UK.
Seven of the nine non-randomised comparative studies 
compared Mepilex Border Sacrum [17–19, 24], Mepilex 
Border Heel [13, 33] or Mepilex Border [23] dressings plus 
standard care with standard care alone. One study compared 
Mepilex Border with a hydrocolloid dressing, both in con-
junction with standard care [36]. One study conducted a 
bilateral comparison of Mepilex Border and a polyurethane 
film dressing applied to the chest and heel [28]. There was a 
wide variation in standard care across the studies, with the 
majority utilising a mixture of components aligned with the 
scope. The studies were generally well matched with the 
scope in terms of their populations and recruitment, recruit-
ing patients at risk or high risk of pressure ulcers in acute 
care settings. All nine studies were conducted outside the 
UK.
The EAC judged that all of the RCTs provided an accept-
able level of internal and external validity with the excep-
tion of one trial [11], which had high internal validity and 
acceptable external validity. Only three observational stud-
ies [23–25] had an acceptable rating for both internal and 
external validity.
The studies reported few outcomes of interest that were 
specified in the scope. The most commonly reported out-
comes were the incidence rate and severity of pressure 
ulcers as assessed using established guidelines [4, 5]. The 
EAC synthesised the results from three RCTs comparing 
Mepilex Border Sacrum to standard care using a fixed-
effect meta-analysis in relation to the number of patients 
developing pressure ulcers. The pooled estimate showed a 
non-statistically significant difference [RR = 0.51 (95% CI 
0.22–1.18), p = 0.12] in favour of Mepilex Border Sacrum 
(see Fig. 2). Results from one study assessing Mepilex Bor-
der Heel and one study assessing Mepilex Border showed a 
statistically significant difference in favour of the interven-
tion (p ≤ 0.001) for pressure ulcer incidence. Where results 
relating to the stage of pressure ulcers were reported, higher 
stage pressure ulcers typically developed in patients not 
receiving the intervention.
Limited evidence was available for other outcomes. In 
terms of patient comfort and satisfaction, results from one 
trial showed that in the majority of self-assessments, patients 
reported the intervention as comfortable [42]. In terms of 
usability, one study stated that there were some difficulties 
associated with reapplying the dressing and keeping it in 
place when patients were restless [25]. Very limited data 
were reported across the studies in relation to complications 
and device-related adverse events.
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The EAC concluded that, despite a relatively large 
body of clinical evidence, there remains uncertainty in the 
treatment effect of Mepilex Border dressings. In particu-
lar, there are limited data for Mepilex Heel and Mepilex 
Border general (applied to the heel or sacrum) dressings, 
patients ‘at risk’ but not ‘at high risk’ of pressure ulcers, 
and paediatric patients. Further, many of the outcomes of 
interest to the decision problem are not addressed by the 
evidence.
4.2  Economic Evidence
4.2.1  Company’s Economic Submission
The company submitted a de novo cost model comparing 
Mepilex Border Sacrum and Heel dressings plus standard 
care pressure ulcer prevention with standard care pressure 
ulcer prevention alone. The EAC deemed the development 
of a de novo model appropriate given the lack of published 
Fig. 1  EAC’s PRISMA diagram. EAC external assessment centre
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UK economic evidence. The analysis had a time horizon 
of under one year and was conducted from an NHS and 
Personal Social Services perspective. A fully executable 
model was produced in Microsoft Excel. The model had a 
simple decision tree structure, where a patient could either 
develop a pressure ulcer or not develop a pressure ulcer. The 
company primarily used data from one RCT, which was con-
ducted in Australia, to populate clinical effectiveness param-
eters for both the Mepilex Border dressings plus standard-
care arm and the standard-care alone arm. Standard-care 
prevention protocols were not explicitly modelled as the 
costs were assumed to be equivalent between both arms. A 
cost-benefit analysis, also conducted in Australia, was used 
to populate resource use parameters for Mepilex Border 
dressings including the number of dressings used and nurse 
time for changing the dressings. All model input parameters 
used in the company’s model are shown in Table 1.
Base-case results from the company’s model estimated 
that Mepilex Border dressings generated cost savings of 
£177 per patient, based on total per patient costs of £231 
in the Mepilex Border dressings arm and £408 in the stand-
ard-care arm. Scenario based and deterministic sensitivity 
analysis was conducted by the company including best- and 
worst-case scenarios which examined the impact of varying 
the incidence of pressure ulcers with Mepilex Border dress-
ings. The majority of analyses returned cost saving results; 
however, not all parameters were included in the sensitivity 
analyses.
4.2.2  Critique of Economic Evidence
The EAC judged the structure of the company’s model to be 
appropriate to the decision problem, capturing the relevant 
costs and consequences of the dressings. The time horizon of 
less than 1 year was considered appropriate given that even 
stage 4 pressure ulcers are expected to heal within 155 days 
[47]. The company’s model did not include any implementa-
tion or training costs associated with the introduction of the 
dressings. This was judged to be appropriate by the EAC 
because free training is provided by the company and staff 
time associated with this was considered to be negligible on 
a per patient basis. Adverse events were also excluded from 
the company’s model. Very little evidence of adverse events 
was identified by the EAC and, where these were identi-
fied, they were associated with very little or no cost. Conse-
quently, the exclusion of adverse events from the economic 
model was considered appropriate by the EAC. The EAC 
replicated the company’s calculations in order to confirm 
their accuracy and identified an error in the way staff costs 
had been applied in the company’s model, causing them to 
be overestimated.
The key critique of the company’s model was that more 
appropriate data could have been used to demonstrate the 
baseline incidence of pressure ulcers and clinical effective-
ness of the dressings. All model inputs were validated by 
the EAC using expert advice and published literature. The 
majority of input parameters were amended by the EAC, as 
shown in Table 2.
Key clinical parameters in the model were the incidence 
of pressure ulcers, both with standard care alone and with 
standard care plus Mepilex Border dressings. The company 
used data from one RCT conducted in a single centre in 
Australia to populate the input parameters for both arms in 
the model [13]. The trial did not give a detailed description 
of standard care and, therefore, it was not possible to ascer-
tain how well this compared with standard care in the UK 
and, consequently, how well the results of the trial could be 
generalised to an NHS setting. The EAC deemed it more 
appropriate to identify a baseline incidence of pressure 
ulcers from a UK-specific source for use in the standard-
care arm. This was then combined with a relative risk from 
the meta-analysis to derive a risk of pressure ulcers in the 
standard care plus Mepilex Border dressings arm.
The source used for the cost of pressure ulcer treatment in 
the company’s model, although UK-specific, was outdated. 
A more recent source was identified and used by the EAC. 
The company also weighted the pressure ulcer treatment 
costs by the stage of pressure ulcers developed, as reported 
by Santamaria et al. [13]. Given the low event numbers in 
this and other trials, this method was deemed by the EAC 
Fig. 2  Pooled analysis: number of patients who developed pressure ulcers (Mepilex Border Sacrum vs Standard Care). CI confidence interval, df 
degrees of freedom
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to be too uncertain. Therefore, the EAC used a UK-specific 
source with high event numbers to weight the costs by stage. 
The staging of pressure ulcers was assumed to be equal in 
both treatment arms because it was not possible to ascer-
tain from the clinical evidence whether the stage of pressure 
ulcer was affected by the Mepilex Border dressings.
The number of dressing changes in the company’s 
model was based on Santamaria et al. [13], an RCT con-
ducted in Australia. This was amended by the EAC using 
data from a single arm observational study conducted in 
the UK because this was judged to be more reflective of 
resource use in the NHS. Minor amendments were also 
made to other resource use parameters, including staff 
costs and dressing costs, in order to incorporate the most 
Table 1  Model input parameters used in the company’s economic model
NHS National Health Service
Parameter Value and range Description
Incidence of pressure ulcer—standard care 13.1%
Range: 5.9% (scenario analysis)
Value used in base case taken from Santamaria et al. 
[13]
This was not varied in deterministic sensitivity 
analysis. A scenario was presented using data from 
Kalowes et al. [11] which combined an incidence of 
5.9% in the standard care arm with an incidence of 
0.7% in the Mepilex Border arm, along with changes 
to other parameters such as pressure ulcer treatment 
costs
Incidence of pressure ulcer—Mepilex Border dress-
ings
3.1%
Range: 0.0–7.7%
Value used in base case taken from Santamaria et al. 
[13]
Varied between 0.0 and 6.2% in deterministic sensitiv-
ity analysis. Justification given was that this was 
double the incidence shown in the Santamaria trial
A threshold analysis was also presented which used 
an incidence of 7.7% in order to return a cost neutral 
result
Cost of pressure ulcer treatment—standard care £3111
Range: £4751
Value used in base case taken from NHS pressure ulcer 
treatment productivity calculator [48] weighted by 
stages of pressure ulcer from Santamaria et al. [13]
Scenario using data from Kalowes et al. [11], also 
presented where NHS pressure ulcer treatment pro-
ductivity calculator costs were weighted by stage of 
pressure ulcer from Kalowes et al. [11]
Cost of pressure ulcer treatment—Mepilex Border 
dressings
£3858
Range: £2000–£3858
Value used in base case taken from NHS pressure ulcer 
treatment productivity calculator [48] weighted by 
stages of pressure ulcer from [13]
Scenario using data from Kalowes et al. [11], also 
presented where NHS pressure ulcer treatment pro-
ductivity calculator costs were weighted by stage of 
pressure ulcer from Kalowes et al. [11]
Total number of Mepilex Border Sacrum dressings 
per patient
2
Range: 1–4
Value used in base case from Santamaria et al. [52] 
Scenarios explored using data from Kalowes et al. 
and doubling and halving dressings required [11]
Total number of Mepilex Border Heel dressings per 
patient
4
Range: 2–6
Value used in base case from Santamaria et al. [52]. 
Scenarios explored doubling and halving dressings 
required
Cost of nurse time per minute £0.51 NHS Agenda for change pay bands 2015, band 6 nurse 
cost used, adjusted for national insurance, superannu-
ation, annual leave, overheads and full-time working 
hours. Not varied in sensitivity analysis
Total number of minutes allowed for all dressing 
changes per patient
12 min
Range: 6–18 min
2 min per dressing change for 6 dressings (2 sacrum, 4 
heel) [52]. Varied between 6 and 18 min to allow for 
more or less dressing changes
Cost of Mepilex Border Sacrum dressing £4.44 Mölnlycke Health Care
Cost of Mepilex Border Heel dressing £7.21 Mölnlycke Health Care
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up-to-date data. In addition, ranges and distributions of 
input parameters were amended by the EAC to those it 
deemed most appropriate.
4.2.3  Additional Work Undertaken by EAC Relating 
to Economic Evidence
A targeted literature search was conducted by the EAC 
to identify a UK-specific incidence of pressure ulcers in 
a population at risk or at high risk of pressure ulcer. The 
NHS safety thermometer was deemed to be the most useful 
source by the EAC because, although a voluntary scheme, 
most NHS trusts submit data every month on the prevalence 
of pressure ulcers, along with other safety measures [48]. 
Prevalence of new pressure ulcers is reported (whereby data 
are recorded on one day each month only and new pressure 
ulcers are those that have occurred since the last month). 
The EAC used this value as a proxy for incidence of pres-
sure ulcers. Due to limitations associated with the data, the 
EAC adjusted the value from the NHS safety thermometer 
to account for known under-reporting and the fact that only 
stage 2 or higher pressure ulcers were reported [49, 50]. The 
value was further adjusted to include only pressure ulcers on 
the heel and sacrum [50].
The targeted search conducted by the EAC also aimed 
to identify evidence on the cost of treating pressure ulcers 
in the UK. Four studies were included, the most useful of 
which was a costing study by Dealey et al. [51]. This study 
costed the treatment of pressure ulcers by stage using a 
‘bottom-up’ methodology. This was based on the resources 
required to deliver protocols of care reflecting good clinical 
practice, with prices reflecting the costs to the health and 
social care system in the UK. To calculate a cost weighted 
by stage of pressure ulcer, the EAC used the proportion of 
pressure ulcers falling into each stage from the NHS safety 
thermometer data, adjusted for missed stage 1 pressure 
ulcers [48, 50].
As well as updating the inputs in the company’s model, 
the EAC ran a number of additional sensitivity and sce-
nario analyses. All parameters were varied individually 
within plausible ranges identified by the EAC, as detailed 
in Table 2. The majority of parameters varied within these 
ranges resulted in increased costs associated with the use 
of Mepilex Border dressings, indicating uncertainty around 
individual input parameters. Probabilistic sensitivity analysis 
(PSA) was included by the EAC to account for combined 
uncertainty in parameters. PSA was run with 2000 iterations 
and included two scenarios. First, pressure ulcer treatment 
costs were varied for both the standard care and Mepilex 
Border dressings arms together, i.e. assuming the stage of 
pressure ulcer was unaffected by the dressings. Second, 
pressure ulcer treatment costs were varied for each of the 
treatment arms independently, i.e. assuming that Mepilex 
Border dressings may result in higher or lower stages of 
pressure ulcer on average. A scenario analysis was run to 
explore the effect of using the alternative relative risk cal-
culated in the meta-analysis, which included the four RCTs 
identified in the EAC’s clinical review. This analysis was 
subject to the strong assumption that the data from San-
tamaria et al. [13] equate to one pressure ulcer per patient. 
Scenarios were also run for use of the sacrum and heel 
dressings separately, whereby the input parameters relating 
to dressing and staff costs and baseline incidence of pres-
sure ulcers were amended to reflect each location of pres-
sure ulcer and dressing variant. A further scenario analysis 
was run to explore the impact of using the Mepilex Border 
general dressing (shape not specific to heel or sacrum) used 
on the heel and sacrum. This scenario assumed the clinical 
efficacy and resource use parameters were equivalent with 
the other dressing variants, and only the costs of the dress-
ings were amended.
Following the EAC’s updates, Mepilex Border dressings 
in combination with standard care were estimated to result 
in cost savings of £19 per patient. This was based on total 
per patient costs of £162 in the Mepilex Border dressings 
arm and £181 in the standard care arm. PSA predicted the 
dressings would be cost saving in 57% of model iterations 
regardless of whether pressure ulcer treatment costs were 
varied independently or together. All scenarios resulted in 
increased cost savings associated with use of the dressings 
(£25–£48 per patient).
5  NICE Guidance
5.1  Provisional Recommendations
The evidence submitted by the company and the EAC’s 
critique of this evidence was presented to the MTAC, who 
provided draft recommendations relating to Mepilex Border 
dressings following their meeting in June 2018. These were 
as follows:
• Mepilex Border Heel and Sacrum dressings show prom-
ise for preventing pressure ulcers in people considered 
to be at risk in acute care settings. However, there is cur-
rently insufficient evidence to support the case for routine 
adoption in the NHS.
• Research is recommended to address uncertainties 
around the claimed benefits of using Mepilex Border 
Heel and Sacrum dressings. This research should also 
explore the incidence of sacrum and heel pressure ulcers 
in NHS acute care settings, and the outcomes from using 
Mepilex Border Heel and Sacrum dressings in addition 
to standard care.
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5.2  Consultation Response
During the consultation, NICE received 12 consultation 
comments from two consultees (the company and an NHS 
professional). Comments regarding the variability in esti-
mates of pressure ulcer incidence and the under-reporting 
of pressure ulcers in the NHS safety thermometer attracted 
a significant amount of discussion. The committee sought 
expert advice on these comments and concluded that based 
on available data, the EAC’s use of the safety thermometer 
data was appropriate.
The provisional recommendation noting a lack of evi-
dence to support routine adoption was challenged by the 
company, who cited that international guidelines have made 
recommendations supporting the use of polyurethane dress-
ings for pressure ulcer prevention. The committee consid-
ered that the provisional recommendation was driven by data 
in the UK rather than data and methods which informed the 
international guideline. The committee also considered that 
medical technologies guidance only considers evidence in 
support of the claimed benefits of a single technology rather 
than a broad review addressing multiple similar technolo-
gies. In addition, none of the expert advice the committee 
heard regarding this issue suggested an amendment to the 
provisional recommendation.
There is a lack of guidance on patient selection. The com-
mittee heard from expert advisers that in practice patient 
selection is not based on a set of rules such as the World 
Union of Wound Healing Societies (WUWHS) algorithm 
because care is often individualised. No amendment was 
made as a result of comments relating to the meta-analysis 
done by the EAC. Minor changes were made to clarify the 
description of the technology.
6  Key Challenges and Learning Points
The key challenges faced by the EAC and the company were 
the issues with generalisability and uncertainty surrounding 
the clinical evidence. Although a reasonable body of evi-
dence exists for Mepilex Border dressings, all of the clinical 
trials were conducted outside of a UK setting. This raised 
uncertainty around whether the evidence from these trials 
could be generalised to the UK NHS, due to potential differ-
ences in standard care pressure ulcer prevention protocols 
and the baseline incidence rate of pressure ulcers. Standard 
care prevention protocols were not always clear in the report-
ing of each of the clinical trials, although in cases where 
they were clear, it was judged that they were consistent with 
standard care in the UK. Expert advice and the existence 
of national prevention guidelines further supported the idea 
that the comparator in the trials was well matched to the 
decision problem [4]. The baseline incidence of pressure 
ulcers estimated for the UK NHS setting by the EAC was 
also well aligned with the three RCTs on which the meta-
analysis was based, and therefore, the scope to benefit from 
Mepilex Border dressings was judged to be broadly similar 
in a UK NHS setting.
Further issues associated with generalisability of the 
clinical evidence related to the patient population in which 
evidence was generated. The majority of the clinical evi-
dence came from studies in a high-risk population and 
there was limited evidence in lower-risk groups. Further, 
there was also a lack of evidence using the Mepilex Border 
Heel variant of the dressing, with all key trials assessing 
the Mepilex Border Sacrum variant and only one non-
randomised comparative trial assessing the effects of the 
Mepilex Border Heel variant of the dressing.
Obtaining an accurate estimate of the baseline inci-
dence of pressure ulcers was difficult. Whilst the NHS 
safety thermometer reports useful information, this was 
limited by likely under-reporting and the exclusion of 
stage 1 pressure ulcers. As described in Sect. 4.2.3, the 
EAC used information from the literature to refine this 
estimate [48, 50]. Despite these efforts, there remained 
uncertainty in the estimate, and clinical experts noted 
the variation in incidence of pressure ulcers between set-
tings and NHS Trusts. However, the use of observational 
or “real world” evidence allowed for a more reasonable 
estimate of baseline pressure ulcer incidence for the UK 
NHS setting than would have been obtained from using 
information from the RCTs instead.
A further challenge was the lack of data and uncertainty 
surrounding some key parameters. After pooling the results 
of three of the key RCTs, although the point estimate was in 
favour of Mepilex Border Sacrum dressings, the difference 
remained statistically insignificant. Additionally, there was 
very limited evidence on the number of dressings required 
per patient to prevent a pressure ulcer, and therefore there 
was also uncertainty around resource use such as nurse time 
associated with application of the dressings. For this reason, 
the costs associated with use of the dressings remain rela-
tively uncertain. It was also not possible to ascertain whether 
the dressings had any impact on the stage of pressure ulcer 
developed due to low event numbers in the trial. Therefore, 
any differences between the two arms in the costs of treating 
pressure ulcers could not be captured in the analysis.
7  Conclusion
The MTEP evaluation process was followed for the develop-
ment of medical technologies guidance on Mepilex Border 
Heel and Sacrum dressings. This included a submission of 
clinical and economic evidence by the company, critical 
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appraisal of this evidence by the EAC, additional work to 
capture available evidence relating to the decision problem 
and address remaining uncertainties, drafting of recommen-
dations by the MTAC, and a subsequent consultation. Fol-
lowing this process, the MTAC judged that Mepilex Border 
Heel and Sacrum dressings have the potential to prevent 
pressure ulcers in people who are considered to be at risk 
in acute care settings, but that further evidence is required 
to address uncertainties around the claimed benefits of the 
dressings and the incidence of pressure ulcers in an NHS 
acute care settings.
Acknowledgements The authors are grateful to the clinical experts 
identified by NICE, who provided expertise and clinical knowledge.
Author contributions The manuscript was prepared by CM and JS with 
contributions from MA, MC, TO, AP, RM and MJ. Literature search-
ing was undertaken by MA and evidence review by CM and MC, with 
advice and quality assurance from RM and MJ. The model critique was 
undertaken by JS and AP, with advice and quality assurance from MJ. 
TO reported the decision problem and the NICE recommendations. 
The guarantor for overall content is MJ.
Compliance with Ethical Standards 
Funding Newcastle upon Tyne Hospitals and York Health Econom-
ics Consortium are funded by NICE to act as an EAC for the Medical 
Technologies Evaluation Programme.
Conflict of interest This summary of the Medical Technology Guid-
ance was produced following publication of the final guidance report. 
This summary has not been externally peer reviewed by Applied 
Health Economics and Health Policy. Seven of the authors (CM, JS, 
MA, MC, AP, RM and MJ) work or worked for the EAC, but otherwise 
have no conflicts of interest. TO is an employee of NICE.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution-NonCommercial 4.0 International License 
(http://creativecommons.org/licenses/by-nc/4.0/), which permits any 
noncommercial use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the 
source, provide a link to the Creative Commons license, and indicate 
if changes were made.
References
 1. National Institute for Health and Care Excellence (NICE). Medi-
cal technologies evaluation programme methods guide. London: 
NICE; 2017.
 2. National Institute for Health and Care Excellence (NICE). Medi-
cal technologies evaluation programme process guide. London: 
NICE; 2017.
 3. National Institute for Health and Care Excellence. Mepilex Border 
Heel and Sacrum dressings for preventing pressure ulcers. 2019. 
https ://www.nice.org.uk/guida nce/mtg40 . Accessed 11 Jan 2019.
 4. National Pressure Ulcer Advisory Panel, European Pressure Ulcer 
Advisory Panel, Pan Pacific Pressure Injury Alliance. Prevention 
and treatment of pressure ulcers: quick reference guide. Haesler 
E, editor.  Australia: Cambridge Media, Perth; 2014. http://www.
npuap .org/wp-conte nt/uploa ds/2014/08/Quick -Refer ence-Guide 
-DIGIT AL-NPUAP -EPUAP -PPPIA .pdf
 5. National Pressure Ulcer Advisory Panel and European Pressure 
Ulcer Advisory Panel. international guideline: pressure ulcer 
treatment technical report. 2009.
 6. Gorecki C, Brown JM, Nelson EA, Briggs M, Schoonhoven L, 
Dealey C, et al. Impact of pressure ulcers on quality of life in older 
patients: a systematic review. J Am Geriatr Soc. 2009;57(7):1175–
83. https ://doi.org/10.1111/j.1532-5415.2009.02307 .x.
 7. Gorecki C, Brown JM, Cano S, Lamping DL, Briggs M, Coleman 
S, et al. Development and validation of a new patient-reported 
outcome measure for patients with pressure ulcers: the PU-QOL 
instrument. Health Qual Life Outcomes. 2013;11:95. https ://doi.
org/10.1186/1477-7525-11-95.
 8. Guy H. Pressure ulcer risk assessment. Nurs Times. 
2012;108(4):16 (8–20).
 9. National Institute for Health and Care Excellence. Pressure ulcers: 
prevention and management. 2014. https ://www.nice.org.uk/guida 
nce/cg179 . Accessed 13 Apr 2018.
 10. Aloweni F, Lim ML, Chua TL, Tan SB, Lian SB, Ang SY. A ran-
domised controlled trial to evaluate the incremental effectiveness 
of a prophylactic dressing and fatty acids oil in the prevention of 
pressure injuries. Wound Pract Res. 2017;25(1):24–34.
 11. Kalowes P, Messina V, Li M. Five-layered soft silicone foam 
dressing to prevent pressure ulcers in the intensive care unit. Am 
J Crit Care. 2016;25(6):e108–19. https ://doi.org/10.4037/ajcc2 
01687 5.
 12. Bao Q, Ji Q. Observation on effect of Mepilex on the prevention 
and treatment of pressure sores. Chin J Med Nurs. 2010. https ://
www.cochr aneli brary .com/centr al/doi/10.1002/centr al/CN-00845 
036/full.
 13. Santamaria N, Gerdtz M, Sage S, McCann J, Freeman A, Vassil-
iou T, et al. A randomised controlled trial of the effectiveness 
of soft silicone multi-layered foam dressings in the prevention 
of sacral and heel pressure ulcers in trauma and critically ill 
patients: the border trial. Int Wound J. 2015;12(3):302–8. https ://
doi.org/10.1111/iwj.12101 .
 14. Santamaria N, Gerdtz M, Kapp S, Wilson L, Gefen A. A ran-
domised controlled trial of the clinical effectiveness of multi-layer 
silicone foam dressings for the prevention of pressure injuries in 
high-risk aged care residents: the border III trial. Int Wound J. 
2018;15:482–90.
 15. Bateman SD, Roberts S. Moisture lesions and associated pres-
sure ulcers: getting the dressing regimen right. Wounds UK. 
2013;9(2):97–102.
 16. Brindle CT. Outliers to the Braden Scale: identifying high-risk 
ICU patients and the results of prophylactic dressing use. World 
Counc Enteros Ther J. 2010;30(1):11–8.
 17. Brindle CT, Wegelin JA. Prophylactic dressing application to 
reduce pressure ulcer formation in cardiac surgery patients. J 
Wound Ostomy Cont Nurs. 2012;39(2):133–42. https ://doi.
org/10.1097/WON.0b013 e3182 47cb8 2.
 18. Chaiken N. Reduction of sacral pressure ulcers in the inten-
sive care unit using a silicone border foam dressing. J Wound 
Ostomy Cont Nurs. 2012;39(2):143–5. https ://doi.org/10.1097/
WON.0b013 e3182 46400 c.
 19. Cubit K, McNally B, Lopez V. Taking the pressure off in the 
Emergency Department: evaluation of the prophylactic appli-
cation of a low shear, soft silicon sacral dressing on high risk 
medical patients. Int Wound J. 2013;10(5):579–84. https ://doi.
org/10.1111/j.1742-481X.2012.01025 .x.
 20. Johnstone A, McGown K. Innovations in the reduction of pressure 
ulceration and pain in critical care. Wounds UK. 2013;9(3):80–4.
464 C. Marshall et al.
 21. Koerner S. Does the use of an absorbent soft silicone self-adherent 
bordered foam improve quality of care by decreasing incidence 
of hospital acquired pressure ulcers? In: Scientific and clinical 
abstracts from the 43rd annual wound, ostomy and continence 
nurses conference, New Orleans, Louisiana; June 4–8; New 
Orleans, Louisiana; 2011. p. 5315.
 22. Padula WV. Effectiveness and value of prophylactic 5-layer foam 
sacral dressings to prevent hospital-acquired pressure injuries 
in acute care hospitals: an observational cohort study. J Wound 
Ostomy Cont Nurs. 2017;44(5):413–9. https ://doi.org/10.1097/
WON.00000 00000 00035 8.
 23. Park KH. The effect of a silicone border foam dressing for pre-
vention of pressure ulcers and incontinence-associated dermati-
tis in intensive care unit patients. J Wound Ostomy Cont Nurs. 
2014;41(5):424–9. https ://doi.org/10.1097/WON.00000 00000 
00004 6 [Erratum appears in J Wound Ostomy Continence 
Nurs. 2014 Nov–Dec;41(6):580].
 24. Richard-Denis A, Thompson C, Mac-Thiong J-M. Effectiveness 
of a multi-layer foam dressing in preventing sacral pressure ulcers 
for the early acute care of patients with a traumatic spinal cord 
injury: comparison with the use of a gel mattress. Int Wound J. 
2017;14(5):874–81. https ://doi.org/10.1111/iwj.12710 .
 25. Santamaria N, Gerdtz M, Liu W, Rakis S, Sage S, Ng AW, et al. 
Clinical effectiveness of a silicone foam dressing for the preven-
tion of heel pressure ulcers in critically ill patients: border II 
trial. J Wound Care. 2015;24(8):340–5. https ://doi.org/10.12968 
/jowc.2015.24.8.340.
 26. Sullivan R. Use of a soft silicone foam dressing to change the 
trajectory of destruction associated with suspected deep tissue 
pressure ulcers. Medsurg Nurs. 2015;24(4):237–42 (67).
 27. Walsh NS, Blanck AW, Smith L, Cross M, Andersson L, Polito C. 
Use of a sacral silicone border foam dressing as one component 
of a pressure ulcer prevention program in an intensive care unit 
setting. J Wound Ostomy Cont Nurs. 2012;39(2):146–9. https ://
doi.org/10.1097/WON.0b013 e3182 43557 9.
 28. Yoshimura M, Ohura N, Tanaka J, Ichimura S, Kasuya Y, Hotta O, 
et al. Soft silicone foam dressing is more effective than polyure-
thane film dressing for preventing intraoperatively acquired pres-
sure ulcers in spinal surgery patients: the Border Operating room 
Spinal Surgery (BOSS) trial in Japan. Int Wound J. 2016. https ://
doi.org/10.1111/iwj.12696 (EPub ahead of print).
 29. Baker G. Nursing driving excellence: preventing pressure ulcers 
in the high-risk population (poster presentation). In: Symposium 
on advance wound care fall; Las Vegas, Nevada, United States of 
America; 2014.
 30. Daukste M. Mepilex border sacrum dressing use for pressure 
ulcers prevention in period of open heart surgery and ICU. Car-
diology. 2013;1:33. https ://doi.org/10.1159/00035 1756.
 31. Edwards MB, Lynch JH. Head over heels for prevention: use of a 
silicone bordered foam heel dressing in the prevention of pressure 
ulcers (poster presentation). In: Symposium on advanced wound 
care fall; Las Vegas, Nevada, United States of America; 2014.
 32. Gentry T, Wright A. The ‘sacral heart’ dressing study: use of an 
absorbent self-adherent soft silicone sacral foam dressing across 
acute care settings (poster presentation). In: The joint conference 
of the Wound Ostomy and Continence Nurses Society and the 
World Council of Enterostomal Therapists; Phoenix, Arizona, 
United States of America; 2010.
 33. Haisley V, Potter K, Wallace J, George R, Betsill K. An ounce 
of prevention: the use of a soft silicone five-layer bordered foam 
heel dressing to decrease the incidence of hospital-acquired heel 
pressure ulcers in an acute care setting. J Wound Ostomy Cont 
Nurs. 2015;42(3):S48–9.
 34. Lientz J, editor. Dollars and sense: economic value in HAPU/
sDTI prevention (poster presentation). In: National pressure ulcer 
advisory panel biennial conference; Houston, Texas, United States 
of America; 2013.
 35. Muldoon C, Grossman N, Lawrence P. Initial use absorbent soft 
silicone self-adherent bordered foam dressing reduces sacral pres-
sure ulcers in the cariovascular ICU (poster presentation). In: The 
joint conference of the Wound Ostomy and Continence Nurses 
Society and the World Council of Enterostomol Therapists; Phoe-
nix, Arizona, United States of America; 2010.
 36. Jin HE. Pressure ulcer prevention using a multi-layer foam dress-
ing with soft silicone (Mepilex Border) during off-pump coronary 
artery bypass graft (OPCABG) surgery. 2018 (unpublished).
 37. Black J, Clark M, Dealey C, Brindle CT, Alves P, Santamaria N, 
et al. Dressings as an adjunct to pressure ulcer prevention: con-
sensus panel recommendations. Int Wound J. 2015;12(4):484–8.
 38. Clark M, Black J, Alves P, Brindle CT, Call E, Dealey C, et al. 
Systematic review of the use of prophylactic dressings in the pre-
vention of pressure ulcers. Int Wound J. 2014;11(5):460–71. https 
://doi.org/10.1111/iwj.12212 .
 39. Cornish L. The use of prophylactic dressings in the prevention 
of pressure ulcers: a literature review. Br J Community Nurs. 
2017;22(Suppl 6):S26–32. https ://doi.org/10.12968 /bjcn.2017.22.
Sup6.S26.
 40. Huang L, Woo KY, Liu LB, Wen RJ, Hu AL, Shi CG. Dressings 
for preventing pressure ulcers: a meta-analysis. Adv Skin Wound 
Care. 2015;28(6):267–73. https ://doi.org/10.1097/01.ASW.00004 
63905 .69998 .0d.
 41. Marshall C, Shore J, Arber M, Cikalo M, Peel A, McCool R et al. 
Mepilex Border Heel and Sacrum dressings for preventing pres-
sure ulcers (assessment report). 2018. https ://www.nice.org.uk/
guida nce/mtg40 /docum ents/asses sment -repor t.
 42. Walker R, Huxley L, Juttner M, Burmeister E, Scott J, Aitken 
LM. A pilot randomized controlled trial using prophylactic dress-
ings to minimize sacral pressure injuries in high-risk hospital-
ized patients. Clin Nurs Res. 2017;26(4):484–503. https ://doi.
org/10.1177/10547 73816 62968 9.
 43. ClinicalTrials.gov. Pressure injury prevention in the ICU with 
multi-layer foam dressings (PUP16_01). Identifier NCT02962882. 
Bethesda (MD): National Library of Medicine (US); 2018. https 
://clini caltr ials.gov/ct2/show/NCT02 96288 2.
 44. Moore ZEH, Webster J. Dressings and topical agents for 
preventing pressure ulcers. Cochrane Database Syst Rev. 
2013;8:CD009362.
 45. National Pressure Ulcer Advisory Panel EPUAPaPPPIA. Preven-
tion and treatment of pressure ulcers: clinical practice guideline. 
Haesler E, editor. Perth, Australia: Cambridge Media; 2014.
 46. Tayyib N, Coyer F. Effectiveness of pressure ulcer prevention 
strategies for adult patients in intensive care units: a systematic 
review. Worldviews Evid Based Nurs. 2016;13(6):432–44. https 
://doi.org/10.1111/wvn.12177 .
 47. National Institute for Health and Care Excellence. Pressure ulcers: 
prevention and management. Appendix L. 2014. https ://www.nice.
org.uk/guida nce/cg179 /evide nce/appen dix-l-pdf-19713 97832 6. 
Accessed 13 Apr 2018.
 48. NHS Improvement. NHS safety thermometer. In: Classic. 2017–
2018. https ://www.safet yther momet er.nhs.uk/index .php/class ic-
therm omete r. Accessed May 2018.
 49. Smith IL, Nixon J, Brown S, Wilson L, Coleman S. Pressure ulcer 
and wounds reporting in NHS hospitals in England part 1: audit 
of monitoring systems. J Tissue Viability. 2016;25(1):3–15. https 
://doi.org/10.1016/j.jtv.2015.11.001.
 50. Clark M, Semple MJ, Ivins N, Mahoney K, Harding K. National 
audit of pressure ulcers and incontinence-associated dermatitis 
in hospitals across Wales: a cross-sectional study. BMJ Open. 
2017;7(8):e015616. https ://doi.org/10.1136/bmjop en-2016-01561 6.
465Mepilex Border Dressings: A NICE Medical Technology Guidance
 51. Dealey C, Posnett J, Walker A. The cost of pressure ulcers in the 
United Kingdom. J Wound Care. 2012;21(6):261–2. https ://doi.
org/10.12968 /jowc.2012.21.6.261 (4, 6).
 52. Santamaria N. Preventing pressure ulcers in aged care: a ran-
domised controlled trial of the effectiveness of prophylactic 
silicone foam dressings. In: 18th EPUAP annual meeting of the 
European pressure ulcer advisory panel; Ghent, Belgium; 2015. 
p. 22.
 53. Personal Social Services Research Unit (PSSRU). Unit costs of 
health & social care 2017. Canterbury: University of Kent; 2017.
